7 Secrets VC Investors Want Biopharma Heads Of R&D To Know
Secret Number One — What Big Pharma Is Doing Right With Its Portfolio
Last summer, the biotechnology industry closed out the second quarter with a 32 percent increase in VC investments when compared to the previous quarter. But as good as 2015 started, quarters three and four seemed to signal the biotech bubble from which investors had been profiting might finally pop.
Last summer, the biotechnology industry closed out the second quarter with a 32 percent increase in VC investments when compared to the previous quarter. But as good as 2015 started, quarters three and four seemed to signal the biotech bubble from which investors had been profiting might finally pop.